Latest News for CYBN
Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could...
CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...
Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...
Cybin operates as Helus Pharma, which is a clinical-stage biotech built around deuterated serotonergic therapies for depression and anxiety. I believe their main value driver is HLP003, which will report in Q4 2026 its Phase 3 APPROACH readout. HELP also recently raised funds in June 2026, and they don't have financial debt. So, they should have enough resources to reach this important milestone later this year.
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CYBN.
Senate Trading
No Senate trades found for CYBN.
U.S. House Trading
No House trades found for CYBN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.